Delphine Davan, EMBA 2018, new VP at Medicenna

Delphine Davan, graduated from the McGill-HEC Montreal EMBA in 2018. She recently joined the Medicenna Therapeutics Corp team. as Vice President of Investor Relations and Corporate Communications.

Medicenna is a clinical stage immunotherapy company that uses directed evolution to generate engineered interleukins called Superkines that can modulate, fine-tune or amplify the immune system in order to combat the most challenging diseases and inspire hope in patients with unmet needs.

“The McGill-HEC Montréal EMBA has completed my Master’s in Cell Biology and my 15 years of experience in business development, mainly in the pharmaceutical industry.

During the program, I have developed a more strategic and structured approach, and also acquired a solid foundation in finance that allowed me to transition my role towards investor relations for biotech companies listed on the TSX and Nasdaq stock markets.”

Delphine Davan, graduated from the McGill-HEC Montreal EMBA in 2018. She recently joined the Medicenna Therapeutics Corp team. as Vice President of Investor Relations and Corporate Communications.